GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Dividend Yield %

Denali Therapeutics (Denali Therapeutics) Dividend Yield % : 0.00% (As of May. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Denali Therapeutics Dividend Yield %?

As of today (2024-05-12), the Trailing Annual Dividend Yield of Denali Therapeutics is 0.00%.

The historical rank and industry rank for Denali Therapeutics's Dividend Yield % or its related term are showing as below:

DNLI's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.44
* Ranked among companies with meaningful Dividend Yield % only.

Denali Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-05-12), the Forward Dividend Yield % of Denali Therapeutics is 0.00%.

Denali Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Denali Therapeutics Dividend Yield % Historical Data

The historical data trend for Denali Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Dividend Yield % Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only - - - - -

Denali Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Denali Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Denali Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Dividend Yield % falls into.



Denali Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Denali Therapeutics  (NAS:DNLI) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Denali Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Denali Therapeutics (Denali Therapeutics) Business Description

Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho officer: Chief Medical Officer C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts director, officer: President and CEO C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes officer: CFO and Treasurer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth officer: COO and Secretary C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne director 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris director 60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton 10 percent owner 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Denali Therapeutics (Denali Therapeutics) Headlines

From GuruFocus

Denali Therapeutics Announces Proposed Offering of Common Stock

By Value_Insider Value_Insider 10-18-2022